Amgen Inc: (NASD: AMGN)

$107.42

-0.52 (-0.48%)

Volume 2,491,210

May 15 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		106.45 - 109.16
	
		52wk Low - High
		67.61 - 114.95
	
		Previous Close
		107.94
	
		Avg. Volume
		4,032,554
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		80.79 B
	
		Div - Yield
		1.88 - 1.74
	
		Beta
		0.41
	
		PE (Forward)
		15.01
	
		Current Year Est.
		7.19
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		79 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/3/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            15.01
                        
                            PEG Ratio
                            1.69
                        
                            Current Year Est.
                            7.19
                        
                            Current Quarter Estimate
                            1.68
                        
                            Most Accurate Estimate
                            1.68
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-25-2013
                        
                            EPS Last Year
                            6.83
                        
                            Expected Earnings Growth
                            8.86%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.   
Full AMGN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
AMGN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.68	1.73	7.19	8.31
Number of Estimates	4	4	4	4
Low Estimate	1.65	1.70	7.16	7.80
High Estimate	1.71	1.80	7.25	NA
Year Ago EPS	1.82	1.67	6.45	7.19
EPS Growth	-7.83%	3.44%	11.51%	15.47%

More AMGN Estimates

Average Earnings Estimates for AMGN

EPS Growth for AMGN

Industry Analysis

Name	Symbol	Previous Close
AMGEN INC	AMGN	107.94
AETERNA ZENTARS	AEZS	1.91
ALKERMES INC	ALKS	31.35
ANIKA THERAPEUT	ANIK	14.10
GENTIUM SPA-ADR	GENT	8.67
NOVELOS THERAPT	NVLT	0.46
TRANZYME INC	TZYM	0.58
AASTROM BIOSCI	ASTM	0.60
ACHILLION PHARM	ACHN	7.30
AFFYMAX INC	AFFY	1.42

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Amgen to Set Up JV in China

May 14, 2013

Stock Market News for May 14, 2013

May 14, 2013

Stock Market News for May 13, 2013

May 13, 2013

Q1 Revenue In-Line. Amgen Deal Is Encouraging

May 10, 2013

Earnings Beat at Hospira

May 01, 2013

Is the Biotech Sector Still a Market Leader?

Apr 25, 2013

Stocks Market News for April 25, 2013

Apr 25, 2013

Tax Benefit Boosts Amgen Earnings

Apr 24, 2013

More AMGN Zacks Commentary

Financials

EPS TTM	6.83
Sales	17,265
Net Income	4,595
Price/Earnings	15.80
Price/Book	4.14
Price/Cash Flow	13.44
Price/Sales	4.63

More AMGN Financials

News

Amgen Tour of California rolls into Santa Clarita - Mcclatchy-Tribune Information Services -- Unrestricted

May 15, 2013

Amgen Tour of California: Peter Sagan's ninth stage victory 'a little bit crazy' - Mcclatchy-Tribune Information Services -- Unrestricted

May 15, 2013

Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States - M2

May 15, 2013

Cycling's Peter Sagan is Tour of California sprint star - Mcclatchy-Tribune Information Services -- Unrestricted

May 15, 2013

Healthcare Businesswomen's Association Southern California Chapter Honors Amgen Executive Qi Jiang as a 2013 "Rising Star" - Businesswire

May 15, 2013

Many Avila Beach businesses hope Tour of California boosts sales - Mcclatchy-Tribune Information Services -- Unrestricted

May 15, 2013

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter - Benzinga

May 15, 2013

Zhejiang Beta Pharma to Form JV with Amgen - Sinocast

May 15, 2013

See All News Stories on AMGN

Broker Recommendations

Current ABR	2.13
ABR (Last Week)	2.17
# of recs in ABR	23
Average Target Price	104.72
Industry Rank by ABR	79 out of 265
Rank in Industry	33 out of 156

More AMGN Broker Recommendations

Day Low - High	106.45 - 109.16
52wk Low - High	67.61 - 114.95
Previous Close	107.94
Avg. Volume	4,032,554
Industry	MED-BIOMED/GENE
Market Cap	80.79 B
Div - Yield	1.88 - 1.74
Beta	0.41
PE (Forward)	15.01
Current Year Est.	7.19
Quarterly Earnings ESP	0.00%

PE (Forward)	15.01
PEG Ratio	1.69
Current Year Est.	7.19
Current Quarter Estimate	1.68
Most Accurate Estimate	1.68
Earnings ESP	0.00%
Next Earnings Report Date	07-25-2013
EPS Last Year	6.83
Expected Earnings Growth	8.86%

Username: Password:

Remember me [?]

Amgen Inc: (NASD: AMGN)

$107.42

-0.52 (-0.48%)

Volume 2,491,210

May 15 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations